紫杉醇腹腔灌注化疗联合替吉奥治疗晚期胃癌患者的临床效果

Paclitaxel Intraperitoneal Perfusion Chemotherapy Combined with Clinical Curative Effect of S-1 in the Treatment of Advanced Gastric Cancer

目的探讨紫杉醇腹腔灌注化疗联合替吉奥治疗晚期胃癌患者的临床效果。方法将40例晚期胃癌患者随机分为对照组和试验组。对照组采用紫杉醇静脉输注联合替吉奥治疗,试验组采用紫杉醇腹腔灌注联合替吉奥治疗。分析两组近期疗效及不良反应。结果试验组有效率(RR)和临床受益率(CBR)均高于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论对于晚期胃癌患者,腹腔灌注紫杉醇较静脉输注紫杉醇不良反应更少,患者耐受性更好,效果更佳,临床易于推广。

Objective Study of paclitaxel intraperitoneal perfusion chemotherapy combined with clinical curative effect of S-1 in the treatment of advanced gastric cancer. Methods 40 cases of advanced gastric cancer patients were randomly assigned to control group（paclitaxel intravenous drip combined with S-1） and observation group（intraperitoneal instillation of paclitaxel combined with S-1）. The short term efficacy and toxic and side effects of the two groups were analyzed. Results The response rate（RR） and clinical benefit rate（CBR） of the observation group were significantly better than those of the control group（P〈0.05）. The toxic and side effects of the observation group were less than those of the control group（P〈0.05）. Conclusion For patients with advanced gastric cancer, intraperitoneal infusion of paclitaxel is with less toxic and side effects than intravenous infusion of paclitaxel, better tolerated by patients, better effective, and it is easy to popularize in the clinical application.